These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21055833)

  • 1. Genetic variability in serotonin receptor and transporter genes may influence risk for tardive dyskinesia in chronic schizophrenia.
    Hsieh CJ; Chen YC; Lai MS; Hong CJ; Chien KL
    Psychiatry Res; 2011 Jun; 188(1):175-6. PubMed ID: 21055833
    [No Abstract]   [Full Text] [Related]  

  • 2. The catechol-O-methyl-transferase gene in tardive dyskinesia.
    Zai CC; Tiwari AK; Müller DJ; De Luca V; Shinkai T; Shaikh S; Ni X; Sibony D; Voineskos AN; Meltzer HY; Lieberman JA; Potkin SG; Remington G; Kennedy JL
    World J Biol Psychiatry; 2010 Sep; 11(6):803-12. PubMed ID: 20586531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia.
    Souza RP; Remington G; Meltzer HY; Lieberman JA; Kennedy JL; Wong AH
    Int Clin Psychopharmacol; 2010 Sep; 25(5):264-9. PubMed ID: 20436352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients.
    Lee HY; Kim DJ; Lee HJ; Choi JE; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):276-80. PubMed ID: 19059448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia.
    Segman RH; Goltser T; Heresco-Levy U; Finkel B; Shalem R; Schlafman M; Yakir A; Greenberg D; Strous R; Lerner A; Shelevoy A; Lerer B
    Pharmacogenomics J; 2003; 3(5):277-83. PubMed ID: 14583797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.
    Zai CC; Tiwari AK; Mazzoco M; de Luca V; Müller DJ; Shaikh SA; Lohoff FW; Freeman N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL
    J Psychiatr Res; 2013 Nov; 47(11):1760-5. PubMed ID: 24018103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
    Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia.
    Lee HJ; Kang SG; Paik JW; Lee MS; Cho BH; Park YM; Kim W; Choi JE; Jung IK; Kim L; Lee MS
    Hum Psychopharmacol; 2007 Dec; 22(8):501-4. PubMed ID: 17726725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.
    Chen CH; Wei FC; Koong FJ; Hsiao KJ
    Biol Psychiatry; 1997 Apr; 41(7):827-9. PubMed ID: 9084902
    [No Abstract]   [Full Text] [Related]  

  • 10. Analysis of genetic variations in the human melatonin receptor (MTNR1A, MTNR1B) genes and antipsychotics-induced tardive dyskinesia in schizophrenia.
    Lai IC; Chen ML; Wang YC; Chen JY; Liao DL; Bai YM; Lin CC; Chen TT; Liou YJ
    World J Biol Psychiatry; 2011 Mar; 12(2):143-8. PubMed ID: 20726823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
    Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T
    Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Genome-wide association analyses for neuroleptic-induced tardive dyskinesia].
    Arinami T; Inada T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Aug; 31(4):155-62. PubMed ID: 21941849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia.
    Fedorenko OY; Loonen AJ; Lang F; Toshchakova VA; Boyarko EG; Semke AV; Bokhan NA; Govorin NV; Aftanas LI; Ivanova SA
    Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25548108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia.
    Souza RP; de Luca V; Meltzer HY; Lieberman JA; Kennedy JL
    Pharmacogenet Genomics; 2010 Apr; 20(4):274-6. PubMed ID: 20168265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
    Basile VS; Ozdemir V; Masellis M; Meltzer HY; Lieberman JA; Potkin SG; Macciardi FM; Petronis A; Kennedy JL
    Mol Psychiatry; 2001 Mar; 6(2):230-4. PubMed ID: 11317228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia.
    Schuhmacher A; Mössner R; Quednow BB; Kühn KU; Wagner M; Cvetanovska G; Rujescu D; Zill P; Möller HJ; Rietschel M; Franke P; Wölwer W; Gaebel W; Maier W
    Pharmacogenet Genomics; 2009 Nov; 19(11):843-51. PubMed ID: 19794330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia.
    Greenbaum L; Alkelai A; Rigbi A; Kohn Y; Lerer B
    Mov Disord; 2010 Dec; 25(16):2809-17. PubMed ID: 20939080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.
    Murata Y; Kobayashi D; Imuta N; Haraguchi K; Ieiri I; Nishimura R; Koyama S; Mine K
    J Clin Psychopharmacol; 2010 Feb; 30(1):11-7. PubMed ID: 20075642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of association of serotonin transporter gene polymorphisms with schizophrenia in a South Indian population.
    Vijayan NN; Iwayama Y; Koshy LV; Natarajan C; Nair C; Allencherry PM; Yoshikawa T; Banerjee M
    J Hum Genet; 2009 Sep; 54(9):538-42. PubMed ID: 19713975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.